Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study

INTRODUCTION: Ipragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test, as well as t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes Ther
Hauptverfasser: Ueno, Hiroaki, Nakazato, Hiroko, Ebihara, Emi, Noma, Kenji, Kawano, Takahisa, Nagamine, Kazuhiro, Sakoda, Hideyuki, Nakazato, Masamitsu
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Healthcare 2018
Schlagworte:
Brief Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5801252/
https://ncbi.nlm.nih.gov/pubmed/29322485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0366-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge